May 12, 2017 Is International ME/CFS and FM Awareness Day
International ME/CFS and FM Awareness Day is May 12th, 2017. Jody Smith shares some information about upcoming events and ways you can be heard ...
Discuss the article on the Forums.

Anti-CD20 Tx Ublituximab Offers Rapid B-Cell Depletion

Discussion in 'Rituximab: News and Research' started by jaybee00, May 31, 2017.

  1. jaybee00

    jaybee00 Senior Member

    Messages:
    103
    Likes:
    121
  2. Marky90

    Marky90 Science breeds knowledge, opinion breeds ignorance

    Messages:
    1,235
    Likes:
    4,580
    I don`t really see the need personally, unless im missing something. My b-cell numbers after rituximab were so low you could not analyse subgroups.. I think what we need is to look into how we can remove b-cells in tissue, and how we can find them.
     
  3. jaybee00

    jaybee00 Senior Member

    Messages:
    103
    Likes:
    121
    Probably true, but
    "Ublituximab is a novel chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. It is glycoengineered to enhance affinity for all variants of receptors, thereby demonstrating greater antibody-dependent cellular cytotoxicity activity than rituximab" ....sounds pretty sexy to me.....
     
    Marky90 likes this.
  4. Marky90

    Marky90 Science breeds knowledge, opinion breeds ignorance

    Messages:
    1,235
    Likes:
    4,580
    Sounds pretty sexy (...What have we become), but isn`t this just a fancy way of saying that its effective in removing b-cells, which Rituximab already is? @Jonathan Edwards
     
  5. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,255
    Likes:
    32,048
    All the new generation anti-CD20 antibodies have these sorts of bells and whistles. This is not the first with glycoengineering. The press release tells us nothing very interesting. They seem to be wanting to sell quick infusions. Trouble is one in a hundred may have serious adverse results if given quickly - like rituximab. Otherwise this is just a basic phase II study showing the drug does what it was supposed to do.

    That is not to say that the progress with anti-CD20 agents recently is not interesting. The do kill more cells these days. But in RA it is not clear that this makes a difference to clinical results as yet. The real problem is what happens when B cells come back, even if you get rid of almost all of them.
     
    Gingergrrl and Marky90 like this.

See more popular forum discussions.

Share This Page